Noxopharm (ASX:NOX) Accounts Payable & Accrued Expense : A$0.30 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Noxopharm Accounts Payable & Accrued Expense?

Noxopharm's quarterly accounts payable & accrued expense declined from Dec. 2022 (A$2.64 Mil) to Jun. 2023 (A$0.72 Mil) and declined from Jun. 2023 (A$0.72 Mil) to Dec. 2023 (A$0.30 Mil).

Noxopharm's annual accounts payable & accrued expense declined from Jun. 2021 (A$6.13 Mil) to Jun. 2022 (A$1.80 Mil) and declined from Jun. 2022 (A$1.80 Mil) to Jun. 2023 (A$0.72 Mil).

Noxopharm Accounts Payable & Accrued Expense Historical Data

The historical data trend for Noxopharm's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noxopharm Accounts Payable & Accrued Expense Chart

Noxopharm Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

1.49

1.79

6.13

1.80

0.72

Noxopharm Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial										1.48	1.80	2.64	0.72	0.30

Noxopharm Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Noxopharm (ASX:NOX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noxopharm Ltd (ASX:NOX) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

NOXOF:USA

Address

60 Linksley Ave, Glenhaven, NSW, AUS, 2156

Website

https://www.noxopharm.com

Noxopharm Ltd is an Australian clinical-stage drug development company focused on treating cancer with Veyonda. It is engaged in the development in the field of both oncology and non-oncology in the pan-pacific region.

Noxopharm (ASX:NOX) Headlines

No Headlines